ReviewBioengineering (Basel, Switzerland)2021
COVID-19 Biomarkers and Advanced Sensing Technologies for Point-of-Care (POC) Diagnosis.
Review in Bioengineering (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Article
- Multi-omics analysis identifies TLRscore for prognostic prediction and highlights TLR8 in macrophage-mediated antitumor immunity of lung adenocarcinoma.Frontiers in immunology · 2026Article
- Enhanced Stability and Sensitivity for CA-125 Detection Under Microfluidic Shear Flow Using Polyethylene Glycol-Coated Biosensor.ACS omega · 2025Article
- Current Scenario in Associating Clinical COVID-19 Biomarkers for Developing Surveillance Platforms.Current medicinal chemistry · 2025Review
- Recent developments in microfluidic passive separation to enable purification of platelets for transfusion.Biomicrofluidics · 2024Review
- The Application of Graphene Field-Effect Transistor Biosensors in COVID-19 Detection Technology: A Review.Sensors (Basel, Switzerland) · 2023Review
- Batteryless wireless magnetostrictive FeSensors and actuators. A, Physical · 2023Article
- Disposable Voltammetric Immunosensor for D-Dimer Detection as Early Biomarker of Thromboembolic Disease and of COVID-19 Prognosis.Biosensors · 2022Article
- Deep Learning for Detecting COVID-19 Using Medical Images.Bioengineering (Basel, Switzerland) · 2022Article
- Angiotensin-Converting Enzyme 2-Based Biosensing Modalities and Devices for Coronavirus Detection.Biosensors · 2022Review
- Advances in Biosensing Technologies for Diagnosis of COVID-19.Biosensors · 2022Review
- AuNP-based biosensors for the diagnosis of pathogenic human coronaviruses: COVID-19 pandemic developments.Analytical and bioanalytical chemistry · 2022Review
- LW-CovidNet: Automatic covid-19 lung infection detection from chest X-ray images.IET image processing · 2022Article
- Article
- Progress and Challenges of Point-of-Need Photonic Biosensors for the Diagnosis of COVID-19 Infections and Immunity.Biosensors · 2022Review
- A proteomics-MM/PBSA dual approach for the analysis of SARS-CoV-2 main protease substrate peptide specificity.Peptides · 2022Article
- Graphite nanocrystals coated paper-based electrode for detection of SARS-Cov-2 gene using DNA-functionalized Au@carbon dot core-shell nanoparticles.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2022Article
- Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections-Overview of Policies Applied in 17 European Countries.Antibiotics (Basel, Switzerland) · 2022Article
- Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 - changing paradigms?ERJ open research · 2022Review
- Microfluidic-Based Novel Optical Quantification of Red Blood Cell Concentration in Blood Flow.Bioengineering (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19, also known as SARS-CoV-2 is a novel, respiratory virus currently plaguing humanity. Genetically, at its core, it is a single-strand positive-sense RNA virus. It is a beta-type Coronavirus and is distinct in its structure and binding mechanism compared to other types of coronaviruses. Testing for the virus remains a challenge due to the small market available for at-home detection. Currently, there are three main types of tests for biomarker detection: viral, antigen and antibody. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) remains the gold standard for viral testing. However, the lack of quantitative detection and turnaround time for results are drawbacks. This manuscript focuses on recent advances in COVID-19 detection that have lower limits of detection and faster response times than RT-PCR testing. The advancements in sensing platforms have amplified the detection levels and provided real-time results for SARS-CoV-2 spike protein detection with limits as low as 1 fg/mL in the Graphene Field Effect Transistor (FET) sensor. Additionally, using multiple biomarkers, detection levels can achieve a specificity and sensitivity level comparable to that of PCR testing. Proper biomarker selection coupled with nano sensing detection platforms are key in the widespread use of Point of Care (POC) diagnosis in COVID-19 detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.